This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Furuta, Y. Articles by Milas, L. Search for Related Content PubMed PubMed Citation Articles by Furuta, Y. Articles by Milas, L.

Increase in Radioresponse of Murine Tumors by Treatment with Indomethacin¹

Departments of Experimental Radiotherapy [Y. F., N. H., L. M.] and Clinical Radiotherapy [T. B.], The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston, Texas; and Department of Internal Medicine [E. H.], University of Texas Medical School, Houston, Texas

Indomethacin, an inhibitor of prostaglandin (PG) synthesis, was investigated for its ability to increase radioresponse of two fibrosarcomas, FSA and NFSA, in C₃Hf/Kam mice. In addition, the effect of indomethacin on radioresponse of hematopoietic tissue, jejunum, hair follicles, and tissues involved in the development of radiation-induced leg contractures was determined. Indomethacin greatly increased radioresponse of 8-mm tumors, as assessed by both tumor growth delay and TCD₅₀ assays. Enhancement factors for tumor growth delay and tumor radiocurability (TCD₅₀) were 1.55 and 1.39, respectively, for FSA, and 1.4 and 1.26, respectively, for NFSA tumors. Of four normal tissues assessed, two (hair follicles and tissues responsible for development of leg contractures) showed no change in radioresponse after treatment with indomethacin, one (hematopoietic tissue) exhibited radioprotection, and one (jejunum) exhibited slight radiosensitization (enhancement factor, 1.12). Therefore, indomethacin significantly augmented tumor radiocurability but had minimal effect on radioresponse of some normal tissues.

¹ This investigation was supported in part by NIH Research Grant CA-06294, awarded by the National Cancer Institute and P01-NS-18494, awarded by National Institutes for Neurological and Communicative Disorders and Stroke. Elizabeth R. Hall is a recipient of a Research Career Development Award (K04-NS00873). Animals used in this study were maintained in facilities approved by the American Association for Accreditation of Laboratory Animal Care and in accordance with current regulations and standards of the U. S. Department of Agriculture and Department of Health and Human Services.

² To whom requests for reprints should be addressed, at Department of Experimental Radiotherapy, University of Texas M.D. Anderson Hospital and Tumor Institute, 1515 Holcombe Boulevard, Houston, TX 77030.

Received 11/ 2/87. Revised 2/19/88. Accepted 2/22/88.

This article has been cited by other articles:

				M. V. Mishra, K. S. Bisht, L. Sun, K. Muldoon-Jacobs, R. Awwad, A. Kaushal, P. Nguyen, L. Huang, J. D. Pennington, S. Markovina, et al. DNMT1 as a Molecular Target in a Multimodality-Resistant Phenotype in Tumor Cells Mol. Cancer Res., February 1, 2008; 6(2): 243 - 249. [Abstract] [Full Text] [PDF]

				K. A. Mason, H. Ariga, R. Neal, D. Valdecanas, N. Hunter, A. M. Krieg, J. K. Whisnant, and L. Milas Targeting Toll-like Receptor 9 with CpG Oligodeoxynucleotides Enhances Tumor Response to Fractionated Radiotherapy Clin. Cancer Res., January 1, 2005; 11(1): 361 - 369. [Abstract] [Full Text] [PDF]

				S. Lanza-Jacoby, A. P. Dicker, S. Miller, F. E. Rosato, J. T. Flynn, S. N. Lavorgna, and R. Burd Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice Mol. Cancer Ther., April 1, 2004; 3(4): 417 - 424. [Abstract] [Full Text] [PDF]

				T. W. Davis, J. M. O'Neal, M. D. Pagel, B. S. Zweifel, P. P. Mehta, D. M. Heuvelman, and J. L. Masferrer Synergy between Celecoxib and Radiotherapy Results from Inhibition of Cyclooxygenase-2-Derived Prostaglandin E2, a Survival Factor for Tumor and Associated Vasculature Cancer Res., January 1, 2004; 64(1): 279 - 285. [Abstract] [Full Text] [PDF]

				H. Choy and L. Milas Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance? J Natl Cancer Inst, October 1, 2003; 95(19): 1440 - 1452. [Abstract] [Full Text] [PDF]

				S. T. Palayoor, P. J. Tofilon, and C. N. Coleman Ibuprofen-mediated Reduction of Hypoxia-inducible Factors HIF-1{alpha} and HIF-2{alpha} in Prostate Cancer Cells Clin. Cancer Res., August 1, 2003; 9(8): 3150 - 3157. [Abstract] [Full Text] [PDF]

				B. B.Y. Ma, R. G. Bristow, J. Kim, and L. L. Siu Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents J. Clin. Oncol., July 15, 2003; 21(14): 2760 - 2776. [Abstract] [Full Text] [PDF]

				P. Wachsberger, R. Burd, and A. P. Dicker Tumor Response to Ionizing Radiation Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring Mechanisms of Interaction Clin. Cancer Res., June 1, 2003; 9(6): 1957 - 1971. [Abstract] [Full Text] [PDF]

				H. Pyo, H. Choy, G. P. Amorino, J.-s. Kim, Q. Cao, S. K. Hercules, and R. N. DuBois A Selective Cyclooxygenase-2 Inhibitor, NS-398, Enhances the Effect of Radiation in Vitro and in Vivo Preferentially on the Cells That Express Cyclooxygenase-2 Clin. Cancer Res., October 1, 2001; 7(10): 2998 - 3005. [Abstract] [Full Text] [PDF]

				C. M. Bradbury, J. E. Locke, S. J. Wei, L. M. Rene, S. Karimpour, C. Hunt, D. R. Spitz, and D. Gius Increased Activator Protein 1 Activity as Well as Resistance to Heat-induced Radiosensitization, Hydrogen Peroxide, and Cisplatin Are Inhibited by Indomethacin in Oxidative Stress-resistant Cells Cancer Res., April 1, 2001; 61(8): 3486 - 3492. [Abstract] [Full Text]

				C. Petersen, S. Petersen, L. Milas, F. F. Lang, and P. J. Tofilon Enhancement of Intrinsic Tumor Cell Radiosensitivity Induced by a Selective Cyclooxygenase-2 Inhibitor Clin. Cancer Res., June 1, 2000; 6(6): 2513 - 2520. [Abstract] [Full Text]

				, , , , , J. , P. , and Preferential Enhancement of Tumor Radioresponse by a Cyclooxygenase-2 Cancer Res., March 1, 2000; 60(5): 1326 - 1331. [Abstract] [Full Text] [PDF]

				L. Milas, K. Kishi, N. Hunter, K. Mason, J. L. Masferrer, and P. J. Tofilon Enhancement of Tumor Response to {gamma}-Radiation by an Inhibitor of Cyclooxygenase-2 Enzyme J Natl Cancer Inst, September 1, 1999; 91(17): 1501 - 1504. [Full Text] [PDF]